US Edition
Rayonier to Present at Upcoming Investor Conferences
TransMedics plans presentations at two major healthcare conferences to update investors on its organ transplant therapy innovations.
- On Feb. 17, 2026, TransMedics announced it will participate in two upcoming investor conferences, according to a PRNewswire release.
- Headquartered in Andover, Mass., TransMedics is a Nasdaq-listed company developing organ transplant therapy for end-stage lung, heart and liver failure.
- Management is scheduled to present at the TD Cowen 46th Annual Health Care Conference in Boston on February 12, 2026, at 1:50 p.m. EST, and virtually at Oppenheimer on February 16, 2026, at 10:00 a.m. EST.
- Targeting investors and analysts, TransMedics schedules in-person fireside chats paired with virtual presentations at March conferences, offering live and remote access.
- Both appearances are scheduled for March 2026, announced via a PRNewswire release from Andover, Mass.
14 Articles
14 Articles
The Daily Press
TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass., Feb. 17, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in…
New Hamburg independent
OrangevilleCricut to Present at Upcoming Investor Conference
SOUTH JORDAN, Utah, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cricut, Inc. (“Cricut”) (NASDAQ: CRCT), the creative technology company that has brought a connected platform for making to millions of users worldwide, today announced that members of its management team are…
INOVIO to Present at Cancer, Investor Conferences
PLYMOUTH MEETING, PA — INOVIO (Nasdaq: INO) announced that it will participate in several upcoming scientific and investor conferences in February and March. The biotechnology company said it will present at the American Association for Cancer Research Immuno-Oncology Conference in Los Angeles on February 18 during Poster Session A from 7:30 p.m. to 10 p.m. PT. The poster presentation is titled “Treatment of RRP with DNA immunotherapy INO-3107 i…
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
